Menu Search
Equities

Procept Biorobotics Corp

PRCT*:MEX

Procept Biorobotics Corp

Actions
  • Price (MXN)1,159.77
  • Today's Change-441.82 / -27.59%
  • Shares traded2.34k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Sep 19 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PROCEPT BioRobotics Corporation is a surgical robotics company, which is focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures and sells the AquaBeam Robotic System, which is an image-guided surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). The AquaBeam Robotic System employs a single-use disposable handpiece to deliver the Company’s proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. The Company designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, (LUTS), due to BPH that are independent of prostate size and shape or surgeon experience.

  • Revenue in USD (TTM)176.58m
  • Net income in USD-103.71m
  • Incorporated2021
  • Employees626.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.